Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Rubius Shares Plunge After Early Data From RTX-240 Solid Tumor Trial

Published 08/04/2022, 19:14
Updated 08/04/2022, 20:11
© Reuters.  Rubius Shares Plunge After Early Data From RTX-240 Solid Tumor Trial

© Reuters. Rubius Shares Plunge After Early Data From RTX-240 Solid Tumor Trial

Rubius Therapeutics Inc (NASDAQ: RUBY) has announced updated data from the ongoing monotherapy Phase 1 arm of the Phase 1/2 trial of RTX-240 in advanced solid tumors.

  • Data were shared at the American Association for Cancer Research Annual Meeting.
  • Nine dose cohorts (n=34) were completed in the monotherapy solid tumor arm.
  • Disease control was observed in 10 patients (1 partial response, 2 unconfirmed partial responses and 7 with stable disease), 9 of whom had experienced disease progression on prior anti-PD-1/anti-PD-L1 therapy.
  • There were three best responses of partial response (PR) in non-small cell lung cancer (NSCLC), anal cancer, and uveal melanoma patients:​
  • Stable disease was observed in 5 patients, including 3 with metastatic NSCLC and 2 with renal cell carcinoma (RCC) across the 3e10 cohorts.
  • The Company has selected a Phase 2 dose of 5e10 cells administered every 3 weeks. This dose will be further explored in the combination expansion cohort of NSCLC and RCC patients.
  • Rubius also announced final results from the Phase 1 arm of monotherapy RTX-240 in relapsed/refractory AML.
  • Seventeen patients were enrolled across four dose levels. No dose-limiting toxicities were observed, and there were 3 treatment-related Grade 3/4 adverse events.
  • There were no investigator-reported immune-related AEs.
  • Five patients had SD greater than 3 months, and 1 patient had a significant blast count reduction (53% to 6%).
  • Price Action: RUBY shares are down 44.4% at $3.26 during the market session on the last check Friday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.